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Abstract
Administration of glucocorticoids and caffeine is a common therapeutic intervention in the neonatal period, but possible
interactions between these substances are still unclear. The present study investigated the effect of caffeine and different
glucocorticoids on expression of surfactant protein (SP)-B, crucial for the physiological function of pulmonary surfactant. We
measured expression levels of SP-B, various SP-B transcription factors including erythroblastic leukemia viral oncogene
homolog 4 (ErbB4) and thyroid transcription factor-1 (TTF-1), as well as the glucocorticoid receptor (GR) after administering
different doses of glucocorticoids, caffeine, cAMP, or the phosphodiesterase-4 inhibitor rolipram in the human airway
epithelial cell line NCI-H441. Administration of dexamethasone (1 mM) or caffeine (5 mM) stimulated SP-B mRNA expression
with a maximal of 38.8611.1-fold and 5.261.4-fold increase, respectively. Synergistic induction was achieved after co-
administration of dexamethasone (1 mM) in combination with caffeine (10 mM) (206659.7-fold increase, p,0.0001) or
cAMP (1 mM) (2136111-fold increase, p = 0.0108). SP-B mRNA was synergistically induced also by administration of caffeine
with hydrocortisone (87.9639.0), prednisolone (154666.8), and betamethasone (12366.4). Rolipram also induced SP-B
mRNA (64.9621.0-fold increase). We detected a higher expression of ErbB4 and GR mRNA (7.0- and 1.7-fold increase,
respectively), whereas TTF-1, Jun B, c-Jun, SP1, SP3, and HNF-3a mRNA expression was predominantly unchanged. In
accordance with mRNA data, mature SP-B was induced significantly by dexamethasone with caffeine (13.869.0-fold
increase, p = 0.0134). We found a synergistic upregulation of SP-B mRNA expression induced by co-administration of various
glucocorticoids and caffeine, achieved by accumulation of intracellular cAMP. This effect was mediated by a caffeine-
dependent phosphodiesterase inhibition and by upregulation of both ErbB4 and the GR. These results suggested that
caffeine is able to induce the expression of SP-transcription factors and affects the signaling pathways of glucocorticoids,
amplifying their effects. Co-administration of caffeine and corticosteroids may therefore be of benefit in surfactant
homeostasis.
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Introduction
Pulmonary surfactant is a complex mixture of 90% lipids and
10% proteins lining the inner epithelium of the alveoli, thereby
stabilizing the surface of the air-blood barrier and improving gas
exchange [1]. The protein fraction of surfactant consists of four
different proteins designated as surfactant protein (SP)-A, -B, -C,
and -D. The hydrophilic proteins SP-A and SP-D have
immunologic properties and are secreted independently from the
remaining components of surfactant [2]. After maturation from
proproteins, the hydrophobic proteins SP-B and SP-C are stored
together with the lipid fraction in the so called lamellar bodies and
are then secreted onto the alveolar surface [3]. The major role of
these two proteins is to maintain the accurate condition of the lipid
surfactant film, although other roles are also discussed [1,4]. SP-B
itself promotes the formation and stability of the surfactant
monolayer through its interactions with dipalmitoyl phosphatidyl-
choline and is mainly synthesized in alveolar type II and Clara
cells, the main producers of surfactant [5]. The thyroid
transcription factor-1 (TTF-1) has an essential role in the
regulation of SP-B transcription [6], while the neuregulin receptor
erythroblastic leukemia viral oncogene homolog 4 (ErbB4) has
been recently described as a new transcription cofactor for SP-B
and, in addition, has a regulatory function which is crucial for fetal
lung development [7,8]. Beside these, various other transcription
factors, like jun B proto-oncogene (Jun B), jun proto-oncogene (c-
Jun), Sp1 transcription factor (SP1), Sp3 transcription factor (SP3),
hepatocyte nuclear factor 3-a (HNF-3a), and cAMP response
element binding.
Protein (CREB) have been also implicated in SP-B transcription
initiation [6,9,10]. The identification of neonates with refractory
respiratory failure due to a genetic absence of SP-B highlights the
importance of SP-B for surfactant function and the maintenance of
lung function [11]. Treatment with surfactant including SP-B has
substantially increased survival rates of preterm infants with
respiratory distress syndrome (RDS) in the last decades [12,13].
As methylxanthine, caffeine is used to reduce the frequency of
apnea of prematurity [14] without inducing short term side effects
[15], thereby facilitates weaning from mechanical ventilation and
extubation in very low birth weight infants [16,17]. Furthermore,
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methylxanthines can reduce the incidence of bronchopulmonary
dysplasia (BPD), most likely by abating the necessity of mechanical
ventilation and their anti-inflammatory properties [15,18]. The
variety of actions mediated by methylxanthines are highly dose
dependent. At higher plasma concentrations methylxanthines act
as unspecific phosphodiesterase (PDE) inhibitors, thereby leading
to higher levels of intracellular cyclic adenosine monophosphate
(cAMP) [19,20]. Moreover, their non-specific adenosine receptor
antagonism has an impact on neurotransmitter release in the
brain, airway smooth muscle constriction in asthmatic patients and
many other physiologic mechanisms influenced by the action of
adenosine [19,21]. A recent study also reported a complex
relationship between high caffeine levels and pro-inflammatory
cytokines [22]. At lower plasma concentrations, a role of
methylxanthines in histone acetylation and deacetylation has been
hypothesized [19,23], which could possibly promote SP gene
transcription mediated by steroids.
Corticosteroids are given to enhance fetal lung function and
maturation [24], thereby affecting the incidence and severity of
RDS [25]. Together with caffeine, glucocorticoids are also
a therapeutic option for BPD [26]. Glucocorticoids act mainly
by binding to the glucocorticoid receptor (GR) and other
transcription factors such as NF-kB to activate or inactivate the
transcription of various genes [27]. However, potential short- and
long term adverse effects of glucocorticoids, especially impairment
of growth and neurodevelopment, should be took into account
before administration to preterm infants [28].
Taken together, caffeine and glucocorticoids are powerful tools
to reduce the incidences of diverse antenatal and postnatal
complications in preterm infants such as BPD and RDS [29,30],
and have been extensively used during the last decades. The
impact of glucocorticoids on various signaling pathways is well
described [31], but consequences of a simultaneous treatment with
caffeine are not sufficiently defined yet. Therefore, it is strongly
desirable to uncover possible interactions both to prevent harmful
side effects or to obtain benefits from these interactions. Since SP-
B is the only surfactant-associated protein which is absolutely
required for postnatal lung function [5], induction of its
transcription and translation is of fundamental importance for
the survival of preterm and full-term infants.
The aim of the present study was to investigate the effect of
caffeine and different glucocorticoids on the expression of SP-B,
since a therapeutic intervention with these two drugs is common
during the neonatal period and possible interactions between the
different signaling pathways activated are not well described yet.
Materials and Methods
Reagents
Caffeine, dexamethasone, betamethasone, prednisone, prednis-
olone, hydrocortisone, 8-Br-cAMP, rolipram, and RU486 were
purchased from Sigma-Aldrich (St. Louis, CA).
Cells
Airway epithelial cells NCI-H441 (H441) [32], a human lung
adenocarcinoma cell line with characteristics of bronchiolar Clara
epithelial cells, and A549 cells [33], a human lung carcinoma cell
line with characteristics of human alveolar basal epithelial cells,
were purchased from ATCC (LGC Standards, Teddington, UK).
H441 and A549 cells were cultured in RPMI 1694 and DMEM
(Gibco, Life Technologies, Carlsbad, CA), respectively, with
additional 5% fetal bovine serum, 100 U/mL penicillin and
100 mg/mL streptomycin (Gibco). Incubation was carried out at
37uC in a humidified atmosphere with 5% CO2.
RNA Extraction and RT-PCR
For RNA extraction, 56105 H441 or 46105 A549 cells were
seeded on six well plates (Greiner, Frickenhausen, Germany) and
grown over night at 37uC. Cells were washed with Dulbecco’s
Phosphate Buffered Saline (DPBS) and treated with 1 mL medium
containing substances as indicated. After the appropriate time,
cells were washed with DPBS and total RNA was isolated using
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. Total RNA was eluted in 50 mL Elution
Buffer and stored at -80uC until reverse transcription. For RT-
PCR, 5 mg of total RNA was reverse transcribed using 1 U M-
MuLV Reverse Transcriptase, 100 pmol Oligo(dT)18 primer, and
1 mM dNTPs (Fermentas, Thermo Scientific, Waltham, US) in
a total volume of 25 mL for 50 min at 42uC. The reaction was
terminated by heating at 70uC for 10 min and first strand cDNA
was stored at 220uC.
Quantitative Real Time RT-PCR (qPCR)
For quantitative detection of human SP-B and b-actin mRNA,
first strand cDNA was diluted 1 to 10 with deionized H2O and
10 mL were analyzed in duplicates of 25 mL reactions using
12.5 mL TaqManH Universal PCR Master Mix (Applied Biosys-
tems, Life Technologies, Carlsbad, CA), 1.5 mL deionized H2O,
and 1 mL FAM-labeled SP-B (Hs00167036_m1), SP-C
(Hs00161628_m1), and b-actin (Hs99999903_m1) probes and
primers (Applied Biosystems), respectively. For quantitative de-
tection of human TTF-1, Jun B, c-Jun, Sp1, Sp3, HNF-3a, ErbB4,
GR, and GAPDH mRNA, first strand cDNA was diluted as above
and 10 mL were analyzed in a 25 mL reaction using 12.5 mL Fast
SYBRH Green Master Mix (Applied Biosystems), 0.5 mL deionized
H2O, and 10 pmol of each forward and reverse primer,
respectively. Primers for detection of Jun B, c-Jun, Sp1, Sp3,
HNF-3a, ErbB4, GR, and GAPDH mRNA were humJunBfwd 59-
AAAGCCCTGGACGATCTG-39, humJunBrev 59-
CTGAGGTTGGTGTAAACGG-39, humc-Junfwd 59-AA-
CATGCTCAGGGAACAG-39, humc-Junrev 59-TCAAGTTCT-
CAAGTCTGTCTC-39, humSP1fwd 59-
GCTGTGGGAAAGTGTATGG-39, humSP1rev 59-
GGCAAATTTCTTCTCACCTG-39, humSP3fwd 59-
CTACCTTGAATACCAATGACC-39, humSP3rev 59-
GTACCTCTTCCACCACCT-39, humHNF-3afwd 59-
GGAACTGTGAAGATGGAAGGG-39, humHNF-3arev 59-
ATGTTGCCGCTCGTAGTC-39, hErbB4fwd 59-ATCATCCA-
CACCTAGTCC-39, hErbB4rev 59-CATCATTCCCTTAGC-
TATCTG-39, hGRfwd 59-CGTTACCACAACTCACCC-39,
hGRrev 59-GTGTAAGTTCCTGAAACCTG-39, hGAPDHfwd
59-CAAAGTTGTCATGGATGACC-39, and hGAPDHrev 59-
CCATGGAGAAGGCTGGGG-39, respectively. Primers for si-
multaneous detection of both TTF-1 mRNA isoforms have
already been described elsewhere [34]. PCRs were performed
on an ABI Prism 7500 Sequence Detection System (TaqManH)
using a 2-step PCR protocol after initial denaturing of DNA
(10 min at 95uC) with 40 cycles of 95uC for 15 s and 60uC for
1 min. In case of measurements including SYBR Green, a melt
curve analysis was performed at the end of every run to verify
single PCR products. Results of SP-B, ErbB4, GR, and TTF-1
were normalized to b-actin or GAPDH and mean fold changes in
mRNA expression were calculated by the DDCT method by Livak
and Schmittgen [35].
Immunoblotting
H441 or A549 cells were rinsed with ice-cold Tris-buffered
saline (TBS) and incubated in 100 mL lysis buffer (Cell Lysis
Buffer; Cell Signaling Technology, Danvers, MA), 0.1 mM PMSF,
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Complete Mini Protease Inhibitor Cocktail, and PhosSTOP
phosphatase inhibitor cocktail (Roche, Basel, Switzerland) for
10 min on ice. The lysate was cleared by centrifugation at
30,0006g for 10 min, and the supernatant was used for Western
immunoblotting analysis. Protein concentrations were determined
for each sample using Bradford assay (Bio-Rad, Richmond, CA),
and equal amounts of cellular protein were loaded and separated
by SDS-PAGE on 10% Bis-Tris gels and electrophoretically
transferred to polyvinylidene diuoride membranes (Amersham
Pharmacia Biotech, Piscataway, NJ). Membranes were blocked in
5% BSA for 1 h at RT and successively incubated with primary
antibodies overnight at 4uC. Western Blots were probed with
primary antibodies to SP-B (sc-13978; Santa Cruz Biotechnology
Inc., Santa Cruz, CA), TTF-1 (sc-13040; Santa Cruz Bio-
technology Inc.), and b-actin (926-42212; LI-COR Inc., Lincoln,
NE), followed by staining with corresponding IRDyeH secondary
antibodies (LI-COR Inc.) for 1 h at RT. Specific protein bands
were visualized using an ODYSSEYH Infrared Imaging System
(LI-COR Inc.). Accumulated signals were quantifieded using
Odyssey Software v2.1 (LI-COR Inc.).
Immunofluorescence Stainings
16105 H441 were seeded on 4 well Lab-TekTM II Chamber
SlideTM System (Nunc) and grown over night at 37uC. Cells were
washed with DPBS and treated with 1 mL medium containing
substances as indicated. After 48 h, cells were fixed and
permeabilized with 4% paraformaldehyde and 0.1% TritonX-
100 in DPBS for 20 min at room temperature (RT) and 10 min at
4uC, respectively. After blocking with DPBS 5% BSA for 20 min
at RT, cells were incubated with 1:100 dilution of rabbit
polyclonal SP-B (Santa Cruz Biotechnology Inc.) antibodies and
incubated overnight at 4uC in a humidified chamber. Cells were
then washed twice with DPBS, stained with 1:200 dilution of Alexa
FluorH 488 goat anti-rabbit IgG (Invitrogen, Life Technologies,
Carlsbad, CA) for 1 h and 300 nM 49,6-Diamidin-2-phenylindol
(DAPI; Invitrogen) for 4 min at RT, respectively. Slides were
washed three times with DPBS and mounted with Fluoromount-
GTM (Southern Biotech, Birmingham, AL). Images were captured
using a DM IRE 220 microscope (Leica, Solms, Germany).
Flow Cytometry
For quantification of SP-B protein levels by flow cytometry,
H441 cells were seeded and treated as described for RNA
extraction, but incubated for 48 h at 37uC. Cells were then
detached using 0.05% Trypsin-EDTA (Gibco), washed twice with
DPBS, and fixed and permeabilized using Fixation Buffer and
Permeabilization Wash Buffer (BioLegend, San Diego, CA),
respectively, as specified by the manufacturer. Subsequently, cells
were stained as described for immunofluorescence stainings
including an additional control using normal rabbit IgG (sc-
3888; Santa Cruz Biotechnology Inc.). For staining of GR, a rabbit
polyclonal antibody (sc-8992; Santa Cruz Biotechnology Inc.) was
used in a 1:100 dilution (kind gift of Dr. Winfried Neuhaus).
Analysis was performed using a FACScan Calibur (Becton
Dickinson, Heidelberg, Germany). Data was analyzed using
FlowJo software (TreeStar, Ashland, OR).
Luciferase Assay
56105 H441 cells were seeded on six well plates (Greiner) and
grown over night at 37uC. Cells were then transfected with 3.5 mg
of a pGL3-based human SP-B promoter construct pGL3hSP-B
(kind gift of Dr. Vijay Boggaram) [36] containing2911/+41 bp of
human SP-B 59 anking DNA and 5 ng of the Renilla luciferase
control reporter vector phRL-TK using 6 mg of linear Poly-
ethylenimine MW 25,000 (Polysciences Inc., Warrington, PA) in
a total volume of 1 mL of Opti-MEMH (Invitrogen) overnight.
Cells were then treated as indicated and after 24 hours luciferase
activity was measured by the dual luciferase assay system (Promega
Biotech Inc., Madison, WI) according to the manufacturer’s
instruction using a Berthold MiniLumat LB 9506 luminometer
(Bad Wildbach, Germany). Firey luciferase activity was normal-
ized by the activity of Renilla luciferase under control of the
thymidine kinase promoter of phRL-TK. Results are given as
relative light units.
Data Analysis
All results shown are combinations of a minimum of three
independent experiments. Results are given as means 6 SD. Data
were analyzed using students t-Test. A p value #0.05 was
considered significant. All statistical analyses were performed using
PrismH version 5.00 (GraphPad Software, San Diego, CA).
Results
Synergistic Effect of Caffeine and Different
Glucocorticoids on Expression of Surfactant Protein B
mRNA
The effect on SP-B mRNA expression of various steroids and
caffeine, alone or in combination, was first measured by qPCR.
Application of dexamethasone to H441 cells increased SP-B
mRNA expression in a dose dependent manner, with highest
induction of 38.8611.1-fold after treatment with 1 mM (Fig. 1A).
Increased induction, albeit to a lower extend, was also observed
after the administration of 5 mM caffeine to H441 cells in a dose
dependent manner leading to a maximal 5.261.4-fold increase of
SP-B mRNA (Fig. 1B). When dexamethasone and caffeine were
given in combination, no additive but rather a synergistic
induction of SP-B mRNA expression could be observed. The
highest stimulation was achieved using 1 mM dexamethasone
together with 10 mM caffeine, leading to 206659.7-fold signifi-
cantly higher levels of SP-B mRNA compared to untreated cells
and 167627.4-fold significantly higher levels if compared to cells
treated with 1 mM dexamethasone (Fig. 1C). The maximal effect
of caffeine and dexamethasone on SP-B mRNA expression was
visible after 24 hours (Fig. 1D). In the lung epithelial cell line
A549, SP-B mRNA could not or barely be detected. In contrast,
SP-B mRNA from A549 cell treated with 1 mM dexamethasone or
10 mM caffeine yielded detectable amounts of SP-B mRNA,
although to a much lower level than in comparison to H441 cells
(difference .10 CT values). If A549 cells treated with combina-
tions of dexamethasone and caffeine were compared to dexa-
methasone-treated cells, a synergistic induction of SP-B mRNA of
31.4611.1-fold could also be observed (Fig. S1).
To test whether the observed effect was restricted to
dexamethasone, we also used different steroids. When adminis-
tered to H441 cells alone, betamethasone determined a 23.966.3-
fold increase in the expression of SP-B mRNA, followed by
a 13.961.0-fold increase for prednisolone, 5.664.0 for hydrocor-
tisone, and 2.560.7 for prednisone (Fig. 2A). When administered
in combination with 10 mM caffeine, almost all glucocorticoids
induced a synergistic upregulation of SP-B mRNA as for
dexamethasone, although to a lower extend. We found
a 12366.4-fold induction of SP-B mRNA for 1 mM betametha-
sone together with 10 mM caffeine compared to untreated cells,
a 154666.8-fold induction for 1 mM prednisolone, and
a 87.9639.0-fold induction for 1 mM hydrocortisone (Fig. 2B).
Prednisone, an inactive form, which is converted to prednisolone
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by 11b-hydroxysteroid dehydrogenase in the liver [37], failed to
mediate the observed synergistic effect (Fig. 2B and Fig. S2).
To identify, whether SP-C is also regulated in a comparable
manner by glucocorticoids and caffeine, we investigated SP-C
mRNA expression of H441 and A549 cells after induction by
qPCR. While changes in SP-C mRNA expression in H441 cells
could not be analyzed since a detection was often barely possible
for every condition, expression in A549 cells was found to be
slightly higher in general, but not regulated (data not shown).
Enhanced Expression of Surfactant Protein B mRNA After
Accumulation of cAMP
At high concentrations, caffeine is known to act as unspecific
inhibitor of PDEs. In order to investigate whether this inhibitory
function is involved in the observed synergistic upregulation of SP-
B mRNA we replaced caffeine with various concentrations of
cAMP to mimic caffeine acivity and performed the same
experiments as above. After the exposure to 1 mM cAMP and
1 mM dexamethasone, an upregulation of SP-B mRNA compa-
rable to the one achieved with caffeine could be observed in H441
cells (2136111-fold increase). As for caffeine, also this effect was
dose dependent (Fig. 3A). Moreover, we also used the PDE4
inhibitor rolipram, which is known to lead to an increased cellular
level of cAMP. While the exclusive treatment with rolipram had
no significant effect on SP-B mRNA expression compared to
untreated cells, we observed a dose-dependent increase of SP-B
mRNA expression when rolipram was administered in combina-
tion with 1 mM dexamethasone compared to cells exposed to
dexamethasone alone (Fig. 3B), which was statistically significant
for 100 mM rolipram (p= 0,0251) and 50 mM rolipram
(p= 0,0165).
Influence of Caffeine and Dexamethasone on mRNA
Expression of Surfactant Protein B Transcription Factors
and SP-B Promoter Activity
To assess which SP-B transcription factors are involved in the
observed upregulatory effect, we measured the mRNA levels of
TTF-1, Jun B, c-Jun, SP1, SP3, HNF-3a, and ErbB4 after
induction of H441 cells with 1 mM dexamethasone, 10 mM
caffeine, or a combination of these drugs. Whereas the transcrip-
tion of TTF-1, c-Jun, SP1, SP3, and HNF-3a mRNA was not
significantly altered by dexamethasone or caffeine alone or in
combination, the expression of ErbB4 mRNA was significantly
upregulated, being the increase about 5.161.9-fold in the presence
of 10 mM caffeine (SEM=1.07, p = 0.0067 compared to un-
treated cells, and p= 0.0308 compared to dexamethasone-treated
cells) (Fig. 4). The addition of 1 mM dexamethasone to cells treated
with caffeine further increased ErbB4 mRNA-levels 7.062.4-fold
Figure 1. Synergistic effect of caffeine and dexamethasone on expression of SP-B mRNA in H441 cells. H441 cells were treated with
different doses of dexamethasone (DXM) (A), caffeine (B), or combinations (C–D), and 24 h later(A–C) or after various timepoints (D) qPCR of SP-B
mRNA was performed. SP-B mRNA levels were normalized to b-actin, and fold differences compared to untreated cells were calculated. For A-C
means 6 SD of at least n = 3 independent experiments are shown. * p,0.05, ** p,0.01 and *** p,0.001 compared to control cells, # p,0.05 and
### p,0.001 compared to cells treated with dexamethasone.
doi:10.1371/journal.pone.0051575.g001
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above control levels (SEM=1.36, p = 0.0036 compared to un-
treated cells, and p=0.0167 compared to dexamethasone-treated
cells), whereas individual treatment with 1 mM dexamethasone
had no effect (Fig. 4). A significant upregulation of 3.160.8-fold
(p = 0.0211) of Jun B mRNA only in case for caffeine-treated cells
in comparison to control cells could also be observed. The
unaltered expression of TTF-1 after treatment of H441 cells with
dexamethasone, caffeine, and combinations was also confirmed at
the protein level by Western immunoblotting (Fig. S3). Addition-
ally, we also measured the same SP-B transcription factor mRNAs
in A549 cells and could confirm the upregulation of ErbB4 mRNA
by caffeine (20.3616.3-fold increase, p= 0.0295) and also by
caffeine in combination with dexamethasone (19.0612.0-fold
increase, p= 0.0102) in comparison to untreated cells (Fig. S4). In
contrast to H441 cells, a significant upregulation of TTF-1 mRNA
could also be observed by caffeine (3.260.8-fold increase,
p = 0.0089) and also by caffeine in combination with dexameth-
asone (13.762.5-fold increase, p = 0.0009) in comparison to
untreated cells (Fig. S4).
When a promoter construct containing -911/+41 bp of human
SP-B 59 anking DNA was tested in a Luciferase reporter assay, the
synergistic induction observed for simultaneous treatment of H441
cells with dexamethasone and caffeine could not be confirmed for
this region of the SP-B promoter. Expression of the Luciferase
reporter gene was only modestly, but significantly altered 1.660.4-
fold (p = 0.0097) after treatment of the cells with 1 mM
dexamethasone (Fig. S5).
Figure 2. Synergistic effect of caffeine and different glucocorticoids on expression of SP-B mRNA in H441 cells. H441 cells were
treated with dexamethasone, betamethasone, prednisone, prednisolone, or hydrocortisone alone (A) or in different concentrations in combination
with caffeine (B). After 24 h qPCR of SP-B mRNA was performed. SP-B mRNA levels were normalized to b-actin, and fold differences compared to
untreated cells were calculated. Means 6 SD of at least n = 3 independent experiments are shown. * p,0.05, ** p,0.01 and *** p,0.001 compared
to control cells.
doi:10.1371/journal.pone.0051575.g002
Figure 3. Enhanced expression of SP-B mRNA after accumulation of cAMP. H441 cells were treated as indicated, and 24 h later qPCR of SP-B
mRNA was performed. SP-B mRNA levels were normalized to b-actin, and fold differences compared to untreated cells were calculated. (A) H441 cells
were treated with dexamethasone, cAMP, or different concentrations of cAMP in combination with dexamethasone. (B) H441 cells were treated with
dexamethasone, the PDE inhibitor rolipram, or different concentrations of rolipram in combination with dexamethasone. Means6 SD of at least n = 3
independent experiments are shown. ** p,0.01 and *** p,0.001 compared to control cells, # p,0.05, ### p,0.001 compared to cells treated
with dexamethasone.
doi:10.1371/journal.pone.0051575.g003
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Involvement of the Glucocorticoid Receptor in
Expression of Surfactant Protein B mRNA
Since the biological effects of glucocorticoids are mediated by
their binding to the GR, a ligand-activated transcription factor
belonging to the steroid/thyroid hormone receptor superfamily,
we investigated whether dexamethasone and caffeine were able to
affect GR mRNA expression. We found that the application of
10 mM caffeine to H441 cells increased GR mRNA expression of
approximately 2-fold (Fig. 5A) as measured by qPCR. This effect
seemed to be unaffected by the addition of 1 mM dexamethasone,
since we could not observe any difference in the GR mRNA
expression between the untreated or the caffeine-treated cells after
its addition. Furthermore, if we added the GR inhibitor RU486
(mifepristone) to dexamethasone and/or caffeine treated cells, the
observed increase of SP-B mRNA expression was completely
abolished and expression was below or comparable to control
levels in all cases (Fig. 5B), indicating an essential role of this
receptor in the regulation of SP-B mRNA expression and in the
observed synergistic effect of dexamethasone and caffeine.
We also measured GR levels by the flow cytometry. In contrast
to mRNA expression, a highly signifcant downregulation of GR
expression of about 66% (p,0.001) could be observed after the
administration of 1 mM dexamethasone, while no significant
modification was detectable after the exposure to 10 mM caffeine
(Fig. 5C–D). However, after a combined treatment with
dexamethasone and caffeine, the GR expression was partially
rescued up to approximately 82% (p= 0.0169) of the GR levels in
untreated cells compared to cells treated with dexamethasone
(Fig. 5D).
Influence of Glucocorticoids and Caffeine on Expression
of SP-B
In order to investigate if the observed synergistic upregulation of
SP-B mRNA by glucocorticoids in combination with caffeine also
occurs at the protein level, we performed Western Blot experi-
ments, immunofluorescence stainings, and flow cytometric anal-
yses of dexamethasone, prednisolone and/or caffeine-treated
H441 cells. Under normal conditions, H441 cells express only
unprocessed or partially processed forms of SP-B (pro-SP-Bs).
To determine, whether dexamethasone, caffeine or the combi-
nation of both are influencing the expression of mature SP-B,
Western Blot experiments were performed. After 48 h of
treatment with dexamethasone, caffeine or combinations, 8–9
kDa mature SP-B could be detected only in cells treated with
dexamethasone and cells additionally treated with caffeine, but not
in untreated cells or cells exclusively treated with caffeine (Fig. 6).
The modest expression of mature SP-B reached 4.665.0-fold
levels in dexamethasone-treated cells and 13.869.0-fold levels
(p = 0.0134) in cells treated with dexamethasone in combination
with caffeine in comparison to untreated cells (Fig. 6). These
results indicate a synergistic effect of steroids and caffeine for
mature SP-B also at the protein level.
When immunofluorescence stainings were performed to mea-
sure pro- and mature SP-B in total (total SP-B), levels were
unaltered 48 hours after the induction with 1 mM dexamethasone
(Fig. S6B) or prednisolone (Fig. S6C) in comparison to untreated
cells (Fig. S6A). In contrast, after the exposure to 10 mM caffeine,
total SP-B levels increased (Fig. S6D). The addition of dexameth-
asone (Fig. S6E) or prednisolone (Fig. S6F) to caffeine-treated cells
did not further increase total SP-B levels. These findings were also
confirmed by flow cytometric analyses of total SP-B. Induction of
additional total SP-B was only initiated by the presence of caffeine,
whereas dexamethasone-treated cells did not differ from untreated
cells in total SP-B-content (Fig. S7A–B).
Discussion
In this study we provide evidence for a synergistic upregulation
of SP-B mRNA in type II pneumocytes induced by a combined
treatment with glucocorticoids and caffeine. We show that this
increase of SP-B mRNA is mediated by an intracellular
enrichment of cAMP and is associated with an upregulation of
the SP-B transcription cofactor ErbB4 as well as the GR. This
synergistic activity mainly affects SP-B mRNA levels and increases
mature SP-B, but has, at least in H441 cells, no further impact on
the caffeine-mediated increase of total SP-B translation.
An induction of SP-B mRNA by dexamethasone and other
glucocorticoids has already been described [38,39,40] and could
be confirmed in this study. The mechanisms leading to an increase
of SP mRNA transcription by glucocorticoids have been already
widely discussed and several transcription factors as well as the GR
have been implicated in this upregulation [6,39,41,42]. It has also
been shown that SP-B mRNA accumulation in H441 cells and
explants is a complex interplay between SP-B gene transcription
Figure 4. Influence of caffeine and dexamethasone on mRNA expression of SP-B transcription factors. H441 cells were treated with
dexamethasone (DXM), caffeine, or combinations and 24 h later qPCR of TTF-1, Jun B, c-Jun, SP1, SP3, HNF-3a, and ErbB4 mRNA was performed.
Transcription factor mRNA levels were normalized to GAPDH, and fold differences compared to untreated cells were calculated. Means 6 SD of at
least n = 3 independent experiments are shown. # p,0.05 compared to cells treated with dexamethasone.
doi:10.1371/journal.pone.0051575.g004
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and modification of SP-B mRNA stability and that posttranscrip-
tional factors also influence SP-B expression [39,43].
Compared to glucocorticoids, we found a slight, dose dependent
induction of SP-B mRNA in H441 cells by caffeine alone, which
has not been described so far. In combination with dexamethasone
and cAMP, isobutylmethylxanthine has been widely used to
preserve the phenotypic characteristics of type II epithelial cells in
cell culture [44,45,46], although an exclusive impact of methyl-
xanthines on the expression of SPs is not well described yet.
Considering the ability of caffeine, like many other methyl-
xanthines, to unspecifically inhibit the activity of PDEs, it seems
plausible that the observed induction of SP-B mRNA expression
by caffeine is mediated by an intracellular enrichment of cAMP,
since this effect could be only observed, if high concentrations of
caffeine were used. In fact, the observed 10-fold higher level of SP-
B mRNA in H441 cells achieved after the exposure to cAMP
alone is in consistence with this assumption and with the so far
reported role of cAMP as inducer of SP-B mRNA expression
[47,48] and enhancer of GR DNA-binding via protein kinase A
[49].
To address, whether the combined treatment of caffeine and
glucocorticoids has any further effect on transcription of SP-B
mRNA rather than simple additive or reductive effects, we
investigated this combined treatment by measuring SP-B mRNA
levels. We found, that all metabolic active glucocorticoids induce
a strong synergistic upregulation of SP-B mRNA if combined with
caffeine. Combinations of dexamethasone, cAMP and isobutyl-
methylxanthine, a competitive non-selective PDE inhibitor [50],
have been described to facilitate differentiation of type II cells from
precursor lung epithelial cells and to synergistically induce the
transcription of a various set of genes, including SP-A, SP-B and
SP-C [43,46,51,52]. By combination of various glucocorticoids
with caffeine rather than with cAMP, we could show a comparable
synergistic induction of SP-B mRNA as previously observed in
cultured human fetal lung epithelial cells using dexamethasone,
cAMP and isobutylmethylxanthine [46]. This may indicate
a common upregulatory mechanism of caffeine, cAMP and PDE
Figure 5. Involvement of the GR in expression of SP-B mRNA. (A) H441 cells were treated with dexamethasone, caffeine, or combinations,
and 24 h later qPCR of GR mRNA was performed. Measured mRNA levels were normalized to GAPDH, and fold differences compared to untreated
cells were calculated. (B) H441 cells were treated with dexamethasone, caffeine, the GR antagonist RU486 (mifepristone), or combinations, and 16 h
later qPCR of SP-B mRNA was performed. Measured mRNA levels were normalized to b-actin, and fold differences compared to untreated cells were
calculated. (C, D) H441 cells were treated with dexamethasone (DXM), caffeine, or combinations. After 48 h, cells were fixed, staining of the GR was
performed, and cells were analyzed by flow cytometry. For A, B and D means 6 SD of n = 3 independent experiments are shown. For C,
a representative image of n = 3 independent experiments is shown. * p,0.05 and *** p,0.001 compared to control cells, ### p,0.001 compared
to cells treated with dexamethasone, 1 p,0.05 compared to cells treated with caffeine, {{{ p,0.001 compared to cells treated with dexamethasone
and caffeine. MFI, mean fluorescence intensity.
doi:10.1371/journal.pone.0051575.g005
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inhibition. By substituting caffeine by cAMP in combination with
dexamethasone and without any additional PDE inhibitors we
could mimic the previously reported synergistic mRNA induction
[46] to the same extend as in combination with caffeine, indicating
an essential mediating role of cAMP in this process.
We found that caffeine contributes to the synergism in SP-B
mRNA induction only at high, non-physiological doses. Supposing
the exclusive role of caffeine as unspecific PDE inhibitor in the
context of the above described synergism, a comparable inhibition
of PDEs using physiological doses of inhibitors could avoid the
usage of high doses of caffeine, thereby eliminating undesirable
side effects but maintaining the synergistic mRNA induction,
which then could be of benefit in surfactant homeostasis. For this
purpose we used the PDE inhibitor rolipram, which is a first
generation PDE4 inhibitor characterized by anti-inflammatory
and anti-immunomodulatory effects [53]. In fact, a dose de-
pendent, significant increase in SP-B mRNA induction was
observed when caffeine was substituted by rolipram. The use of
selective PDE inhibitors of the second generation such as the
PDE4 inhibitors cilomilast and roflumilast, exhibiting longer half-
lives and fewer side effects, may further increase intracellular
cAMP levels and thus also potentially therapeutic SP-B levels [54].
The therapeutic potential of PDE4 inhibitors was further
demonstrated by their administration to different animal models
with lung diseases, in whom they have been shown to improve
lung alveolarisation [55] and to attenuate persistent lung injury
[56].
To address, which mechanisms are directly responsible for the
observed SP-B mRNA upregulation induced by caffeine, we first
measured the mRNA levels of TTF-1, the most important
transcription factor involved in SP mRNA transcription [57,58].
However, the reported induction of TTF-1 mRNA expression by
dexamethasone and cAMP [46,52] could be confirmed by qPCR
only in A549, but not H441 cells after the treatment with caffeine
instead of cAMP. A possible explanation for this disagreement
could be the accessibility to different regulatory mechanisms
leading to SP gene transcription in fetal or different lung epithelial
cell subtypes versus H441 cells, which are derived from adult
papillary adenocarcinoma cells, since it is known that other factors
play a central role in cell specific activation of SP genes [6]. The
hypothesis that glucocorticoids restore TTF-1 and SP-B levels by
increasing the TTF-1 autoregulatory mechanism only in hypo-
plastic fetal lungs supports this possibility [59]. Since it is known
that cAMP is able to mediate conformational changes in protein
kinase A, which lead to the phosphorylation of TTF-1 [6,60], an
involvement of TTF-1 in the observed SP-B mRNA induction in
H441 cells could also be explained by its phosphorylation rather
than by its upregulation.
One other recently identified transcriptional cofactor of the SP-
B gene is ErbB4 [8]. It has been already associated with the
induction of fetal surfactant phospholipid synthesis [61] and seems
to have a crucial regulatory role in fetal lung development [62].
We found that caffeine, but not dexamethasone, is able to induce
an increase in ErbB4 mRNA in H441 cells and in A549 cells.
Therefore, ErbB4 may contribute to the observed caffeine-induced
expression of SP-B mRNA and its synergistic induction in
combination with dexamethasone. The examination of other SP-
B transcription factor mRNAs like Jun B, c-Jun, SP1, SP3, and
HNF-3a indicated no involvement in the described synergism.
To directly examine the influence of SP-B transcription factors,
we performed SP-B promoter analyses. By this, an approximately
900 bp promoter-region of human SP-B investigated in luciferase
assays was not reflecting the same synergistic effects for the
reporter gene. These results are indicating a more complex
regulation of SP-B mRNA transcription initiation, which may
include other factors like cis- or trans-activating elements in
combination. Additionally, an increase of SP-B mRNA stability is
neither be detectable by the investigation of the SP-B promoter-
region. For glucocorticoids this has been previously shown using
also H441 cells, where it was postulated that the influence of
glucocorticoids on SP-B mRNA expression is more likely due to
changes in mRNA stability rather than enhanced transcription
[6,39].
Besides influencing SP-B transcription factors, a modification of
the glucocorticoid signal transduction pathway by caffeine could
be an explanation for the observed synergistic induction of SP-B
mRNA expression by caffeine and glucocorticoids, since it is
known that the action of glucocorticoids is mediated by the GR
[63]. We found a slight upregulation of GR mRNA after induction
with caffeine, which was not modified by the addition of
dexamethasone. Some authors already reported an upregulation
of both GR mRNA and protein levels by glucocorticoids in various
cell lines of lymphoid leukemias [64] and a caffeine-mediated
enhancement of GR activity in human osteoblastic cells [65]. Flow
cytometric measurement of GR protein levels revealed a down-
regulation of the GR by dexamethasone, which could be partly
restored by the addition of caffeine. This would indicate that
caffeine influences the ability of glucocorticoids to increase SP-B
mRNA levels by modifying GR expression and therefore possibly
reversing the same inhibitory effects of glucocorticoids on SP-B
mRNA transcription as shown for SP-A mRNA [66]. Therefore,
Figure 6. Influence of dexamethasone and caffeine on
expression of mature SP-B. H441 cells were treated with 1 mM
dexamethasone, 10 mM caffeine, or combinations. After 48 h, cells
were lysed and Western immunoblotting analysis against SP-B was
performed using a polyclonal antibody. Relative expression levels of SP-
B were calculated by normalizing signals to detected b-actin levels.
Whereas in untreated cells or cells treated with 10 mM caffeine no
mature SP-B could be detected, the expression of mature SP-B in H441
cells was modestly induced by dexamethasone and significantly
induced in cells additionally treated with caffeine. Data represent
means 6 SD of n= 3 independent experiments. * p,0.05 compared to
control cells.
doi:10.1371/journal.pone.0051575.g006
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reversing this inhibitory effect on transcription, the enhanced
mRNA stability mediated by glucocorticoids [6] could lead to
enormous new amounts of SP-B mRNA, which explains the
synergistic induction reported here.
The enhancement of SP-B mRNA by glucocorticoids alone and
the synergistic induction by dexamethasone in combination with
caffeine was completely abolished by the addition of the GR-
inhibitor RU486, which indicates a major involvement of the GR
signaling pathway.
When investigating the induction of SP-B by caffeine and
glucocorticoids at the protein level, different results were obtained,
depending on whether mature or total SP-B (including mature and
un- or partially processed forms of SP-B) was investigated. If the
mature form of SP-B was analysed by immunoblotting, we found
these fully processed form induced by dexamethasone and also
significantly to a larger extend by the combination of dexameth-
asone and caffeine, while no mature SP-B could be detected in
untreated cells and cells treated with caffeine alone. This is also in
accordance with the observation of previous studies, which claim
that SP-B is not fully processed in untreated H441 cells [1]. It also
further indicates that parts of the cellular machinery responsible
for the final processing of pro-SP-B are inducible by glucocorti-
coids and, to a higher extent, by their combination with caffeine in
H441 cells. When the content of total SP-B was investigated by
immunofluorescence and flow cytometry, only a slight but marked
increase was obtained by the induction with caffeine. The pro-
forms of SP-B are abundantly expressed in H441 cells and may
therefore represent static forms which may be affected differently
or not affected at all by glucocorticoids in combination with
caffeine. Changes of mature SP-B were masked by the detection of
the pro-SP-B forms in immunofluorescence stainings. We there-
fore speculate that caffeine-induced inhibition of PDE and the
subsequent increase of cellular cAMP levels are only influencing
SP-B mRNA transcription and processing of pro-SP-B forms, but
have no impact on caffeine-mediated increase of SP-B translation.
Conclusion
In conclusion, we described a synergistic upregulation of SP-B
mRNA in H441 and A549 cells induced by glucocorticoids in
combination with caffeine, which was associated with increased
levels of the GR and of the SP-B transcription cofactor ErbB4.
Our results indicate that basic SP-B mRNA transcription initiated
by glucocorticoids can be potentiated via an increase of cellular
cAMP, achieved by a caffeine-mediated inhibition of PDEs. These
findings may contribute to our understanding of how the
expression of SP genes is regulated. Therefore, the administration
of caffeine in combination with glucocorticoids may be of benefit
in surfactant homeostasis during the treatment of preterm infants.
Supporting Information
Figure S1 Synergistic effect of caffeine and dexameth-
asone on expression of SP-B mRNA in A549 cells. A549
cells were treated with 1 mM dexamethasone, 10 mM caffeine, or
combinations, and 24 h later qPCR of SP-B mRNA was
performed. SP-B mRNA levels were normalized to b-actin, and
fold differences compared to cells treated with dexamethasone
were calculated. Means 6 SD of n= 3 independent experiments
are shown. ### p,0.001 compared to cells treated with
dexamethasone.
(TIF)
Figure S2 Chemical structures of different glucocorti-
coids. Oxygen is highlighted in red. The 11-keto group of the
physiologically inactive prednisone, absent in all other glucocorti-
coids, is highlighted in green.
(TIF)
Figure S3 Influence of dexamethasone and caffeine on
expression of TTF-1. H441 cells were treated with different
doses of dexamethasone, 10 mM caffeine, or combinations. After
48 h, cells were lysed and Western immunoblotting analysis
against TTF-1 was performed using a polyclonal antibody.
Relative expression levels of TTF-1 were calculated by normal-
izing signals to detected b-actin levels.
(TIF)
Figure S4 Influence of caffeine and dexamethasone on
mRNA expression of SP-B transcription factors in A549
cells. A549 cells were treated with dexamethasone (DXM),
caffeine, or combinations and 24 h later qPCR of TTF-1, Jun B,
c-Jun, SP1, SP3, HNF-3a, and ErbB4 mRNA was performed.
Transcription factor mRNA levels were normalized to GAPDH,
and fold differences compared to untreated cells were calculated.
Means 6 SD of at least n = 3 independent experiments are shown.
* p,0.05 and ** p,0.01 compared to control cells, # p,0.05,
## p,0.01 compared to cells treated with dexamethasone.
(TIF)
Figure S5 Influence of dexamethasone and caffeine on
SP-B promoter activity. H441 cells were transfected with
a human SP-B promoter construct containing 2911/+44 bp of
the human SP-B 59-anking DNA linked to a luciferase reporter
gene. 16 h later cells were treated with 1 mM dexamethasone,
10 mM caffeine, or combinations, and 24 h later luciferase activity
was measured and normalized to the activity of a cotransfected
plasmid containing Renilla luciferase under control of the
thymidine kinase promoter. Only in cells treated with dexameth-
asone, a significant increase of SP-B promoter activity could be
detected. Data represents means 6 SD of n= 3 independent
experiments measured in duplicates or triplicates. ** p,0.01
compared to untreated cells.
(TIF)
Figure S6 Influence of glucocorticoids, caffeine and
cAMP on expression of total SP-B. H441 cells were treated
with 1 mM dexamethasone, 1 mM prednisolone, 10 mM caffeine,
1 mM cAMP, or combinations. After 48 h, cells were fixed, and
immunofluorescence stainings against total SP-B (green) were
performed. Nuclei were counterstained with DAPI (blue). Whereas
total SP-B expression in untreated cells was low (A), the treatment
with caffeine induced an increased expression (D). Simultaneous
treatment with either dexamethasone (E) or prednisolone (F) had
no additional effect. Individual treatment with either dexameth-
asone (B) or prednisolone (C) did not increase total SP-B levels in
comparison to untreated cells. Representative images of n = 3
independent experiments are shown.
(TIF)
Figure S7 Flow cytometric analysis of total SP-B in H441
cells treated with dexamethasone and/or caffeine. H441
cells were treated with 1 mM dexamethasone (DXM), 10 mM
caffeine, or combinations and 48 h later cells were fixed, staining
of total SP-B was performed, and total SP-B levels were measured
by flow cytometry. (A) Representative histogram of n= 3 in-
dependent experiments. (B) Mean fluorescence intensity (MFI)
values for total SP-B are shown as means 6 SD of n= 3
independent experiments. * p,0.05 compared to control cells.
(TIF)
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